http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111374986-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e9297c8f247b3724a04ec3c3130f182 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-714 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-15 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-714 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 |
| filingDate | 2018-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_372b08e246df8f65dec8c6ceb6c452f4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_706a55ebd2ed7688d273904032288205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e305d65246be138b6879290ea7dedbf4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad6f5c130e867b6e1bfd75d7ac05d060 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d1091d11a7daa3d4ac85faf44444281 |
| publicationDate | 2020-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111374986-A |
| titleOfInvention | Use of vitamin B12 as α-synuclein aggregation inhibitor in the preparation of medicines, health products or food |
| abstract | The invention proposes the use of vitamin B12 as an α-synuclein aggregation inhibitor in the preparation of medicines, health-care products or food, and belongs to the technical field of medicine, health-care products or food. Use of vitamin B12 in the preparation of medicines, health products or foods for preventing and/or treating diseases characterized by aggregation and precipitation of α-synuclein. The application of vitamin B12 in inhibiting the aggregation of α-synuclein proposed by the present invention can effectively inhibit the aggregation of α-Syn, effectively prevent the occurrence of PD and delay the development of PD. Moreover, it effectively inhibits the toxicity of α-Syn aggregates to cells, and inhibits the aggregation of α-Syn and its conformational change process. It is an ideal drug for the treatment and prevention of Parkinson's disease. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111991412-A |
| priorityDate | 2018-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 62.